Vol. 5 No. 1 (2018): January-December 2018

DOI: https://doi.org/10.1177/2284240318807726
Published: 2018-12-31

Original Research Articles

  • Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group

    Francesco S. Mennini, Raffaella Viti, Chiara Bini, Andrea Marcellusi, Fabio Palazzo
    DOI: https://doi.org/10.33393/grhta.2018.446

  • Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis

    Carlo Piccinni, Letizia Dondi, Giulia Ronconi, Antonella Pedrini, Nello Martini, Giulio Marchesini
    DOI: https://doi.org/10.33393/grhta.2018.449

  • Assessing social and economic impact of subcutaneous mAbs in oncology

    Americo Cicchetti, Silvia Coretti, Daniele Mascia, Nicola Mazzanti, Pietro Refolo, Francesca R. Rolli, Filippo Rumi
    DOI: https://doi.org/10.33393/grhta.2018.443

  • A comparative examination of healthcare use related to hearing impairment in Europe

    Mimi Xiao, Ciaran O’Neill
    DOI: https://doi.org/10.33393/grhta.2018.450

  • Budget impact analysis of different rapid-acting insulin analogues in Italy

    Elena P. Lanati, Paola La Malfa, Arianna Iorio, Francesco S. Mennini, Francesca Fanelli, Sandro Gentile
    DOI: https://doi.org/10.33393/grhta.2018.448

  • Budget Impact analysis on models of purchase and management of aids for urinary incontinence compared

    F.S. Mennini, P. Pisanti, S. Terzoni, E.P. Lanati, A. Marcellusi, A. Marcelli, A. Iorio
    DOI: https://doi.org/10.33393/grhta.2018.447

  • Budget impact analysis of the etanercept biosimilar: the Italian scenario

    Roberto Ravasio, Giampiero Girolomoni, Roberto Gorla
    DOI: https://doi.org/10.33393/grhta.2018.444

  • Patients’ Associations and HTA for medicines: actual and future role in Italy

    Claudio Jommi, MSc, Arianna Bertolani, Phd
    DOI: https://doi.org/10.33393/grhta.2018.445

  • The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes

    Roberto Ravasio, Giorgio Grassi
    DOI: https://doi.org/10.33393/grhta.2018.442

  • The hospitalization burden of influenza: just the tip of the iceberg?

    Arianna Bertolani, Giovanni Fattore, Fabrizio Pregliasco
    DOI: https://doi.org/10.33393/grhta.2018.439

  • Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy

    Sanja Stanisic, Alessia Marocco, Anna Gallo, Paolo Rama, Marta Sacchetti, Maurizio Rolando, Augusto Pocobelli, Roberto Ceccuzzi, Andrea Leonardi, Rita Mencucci, Emilio Pedrotti, Elisa Postorino, Maurizio Mascia, Lucia R Mazzamuto, Luisanna Prisco, Floortje Van Nooten, Patrizia Berto
    DOI: https://doi.org/10.33393/grhta.2018.437

  • Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective

    Alessia Marocco, Sanja Stanisic, Francesca Fanelli, Francesco Damele, Furio Colivicchi
    DOI: https://doi.org/10.33393/grhta.2018.438

  • Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

    Carla Rognoni, Arianna Bertolani, Claudio Jommi
    DOI: https://doi.org/10.33393/grhta.2018.440

  • Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study

    Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi, Angelo Guido Corsico
    DOI: https://doi.org/10.33393/grhta.2018.436

  • Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy

    Sanja Stanisic, Americo Cicchetti, Camillo Porta, Giuseppe Procopio, Patrizia Berto
    DOI: https://doi.org/10.33393/grhta.2018.434

  • Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

    Roberto Ravasio, Silvia Antonelli, Veronica Rogai, Walid Fakhouri, Jean Philippe Capron, Serena Losi
    DOI: https://doi.org/10.33393/grhta.2018.435

  • Early access to the market: from the conditional approvals of the EMA to the specific contractual agreements of AIFA

    Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
    DOI: https://doi.org/10.33393/grhta.2018.430

  • Access times to medicines in Italy in the period 2015-2017: Analysis of the evaluation times of the Italian Medicines Agency

    Dario Lidonnici, Virginia Ronco, Martina Isernia, Elena Lanati, Claudio Jommi, Pier Luigi Canonico, Armando A. Genazzani
    DOI: https://doi.org/10.33393/grhta.2018.433

  • The costs of patients with inflammatory bowel diseases (Crohn's disease and ulcerative colitis). Real world study in Italy

    Stefano Capri, Antonio Russo
    DOI: https://doi.org/10.33393/grhta.2018.431

  • Treatment with intravitreal anti-VEGF drugs in naïve patients in Italy

    M. Albrecht, M. Nica, D. Colombo, C. Ferri, P. Tadini, U. Introini, F. Bandello
    DOI: https://doi.org/10.33393/grhta.2018.432

  • Evaluation of the budgetary impact of the comprehensive nutritional home care service

    Javier Nuñez Alfonsel, Benedetto Ielpo, Villareal García-Lomas M, Cristóbal Belda Iniesta
    DOI: https://doi.org/10.33393/grhta.2018.428

  • Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study

    Andrea Aiello, Daniela Ritrovato, Claudia Pitotti
    DOI: https://doi.org/10.33393/grhta.2018.429

  • A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital

    Alan Kearney, Elaine K Walsh, Ann Kirby, Ciaran Halleran, Derina Byrne, Jennifer Haugh, Laura J Sahm
    DOI: https://doi.org/10.33393/grhta.2018.427

Erratum

  • Corrigendum

    DOI: https://doi.org/10.33393/grhta.2018.441